Yevgeniya Mykhaylevska
Psychiatric/Mental Health · Saint Louis, MONPI 1548974066
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 261 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 27.6% of the total. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $34.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Vanda Pharmaceuticals Inc.$758
- E.r. Squibb & Sons, L.L.C.$636
- AbbVie$635
- Alkermes, Inc.$427
- plus $2K from 19 others
What the payments were for
- Food & beverage$8,97899%
- Education$611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 88 | $2,495 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 47 | $1,609 |
| Vanda Pharmaceuticals Inc. | 9 | $758 |
| E.r. Squibb & Sons, L.L.C. | 19 | $636 |
| AbbVie | 20 | $635 |
| Alkermes, Inc. | 8 | $427 |
| Tris Pharma Inc | 15 | $366 |
| Neurocrine Biosciences, Inc. | 15 | $341 |
| Johnson & Johnson | 4 | $257 |
| Axsome Therapeutics, Inc. | 5 | $242 |
| Acadia Pharmaceuticals Inc | 6 | $217 |
| Collegium Pharmaceutical, Inc. | 4 | $146 |
| Luye Pharma (USA) Ltd. | 2 | $145 |
| Supernus Pharmaceuticals, Inc. | 1 | $125 |
| Novo Nordisk | 1 | $125 |
| Harmony Biosciences LLC | 5 | $125 |
| Bioxcel Therapeutics, Inc. | 1 | $120 |
| Ironshore Pharmaceuticals Inc. | 2 | $105 |
| Bausch Health US, LLC | 2 | $45 |
| Indivior Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Almatica Pharma LLC | 1 | $16 |
| Pfizer | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$1,072
- LYBALVI$975
- Austedo XR$822
- Fanapt$721
- ARISTADA$498
- UZEDY$472
- COBENFY$358
- VRAYLAR$357
- INVEGA SUSTENNA$146
- INGREZZA$125
- Wegovy$125
- QELBREE$125
- JORNAY PM$125
- ARISTADA INITIO$125
- ERZOFRI EXTENDED-RELEASE$123
- Dyanavel XR$121
- Quillivant$121
- Quillichew ER$121
- IGALMI$120
- Auvelity$108
How this compares
$9,039 in reported general payments places this provider in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 35 | $221,108 |
| IngrezzaValbenazine Tosylate | 32 | $196,431 |
| CaplytaLumateperone Tosylate | 11 | $20,723 |
| VraylarCariprazine Hcl | 12 | $17,454 |
| Aripiprazole | 26 | $2,551 |
| Sertraline Hcl | 143 | $1,690 |
| Buspirone Hcl | 120 | $1,518 |
| Duloxetine Hcl | 43 | $1,268 |
| Divalproex Sodium | 40 | $1,127 |
| Hydroxyzine Hcl | 39 | $1,062 |
| Memantine Hcl ErMemantine Hcl | 13 | $1,033 |
| Haloperidol Decanoate | 13 | $944 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $882 |
| Quetiapine Fumarate | 74 | $881 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $2,495 | $221,10835 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $341 | $196,43132 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,609 | $20,72311 claims |
| AbbVieVraylar | $635 | $17,45412 claims |
| Almatica Pharma LLCSertraline Hcl | $16 | $1,690143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Saint Louis
- Aldijana SacicSaint Louis$510K
- Julie WaterburySaint Louis$135K
- Melinda SmithSaint Louis$13K
- Richard YakimoSaint Louis$10K
- Anastasia AmiramovaSaint Louis$9K
- Jessica BurichSaint Louis$8K
- Jennifer ArmstrongSaint Louis$8K
- Bonnie HuffSaint Louis$7K
- Jacqueline KirkSaint Louis$6K
- Danielle RoncoSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.